Overview of CRISPR
CRISPR is an innovative tool that is changing lives and creating significant advancements in the medical sector. The acronym CRISPR refers to “Clustered Regularly Interspaced Short Palindromic Repeats,” which exist in prokaryotes—tiny, single-celled entities devoid of organelles. These sequences reside within the genomes of prokaryotes, which organize a cell’s DNA in clusters.
As a tool for gene editing, CRISPR is employed to alter specific DNA segments to address serious health issues. It is particularly valuable in defending the body against viral attacks by integrating the foreign DNA into its genome, enabling recognition and elimination of the virus during subsequent encounters. Notably, in comparison to other gene editing techniques, CRISPR is significantly more accurate and simpler to utilize, facilitating an easier process for redesigning sequences. While many gene-editing instruments typically depend on a single protein, CRISPR utilizes RNA-guided targeting along with the Cas9 enzyme.
The Mechanism of CRISPR
CRISPR operates by leveraging a natural defense system found in bacteria that enables them to detect and eradicate viral threats. Upon a virus invading a bacterial cell (a prokaryote), the bacterium retains a portion of the invader’s DNA in its own genome as a genetic “memory.” This ability allows the bacterium to identify and react more efficiently to future viral assaults.
For gene editing purposes, this mechanism is modified with two essential components: the Cas9 enzyme, which acts like molecular scissors to cleave DNA, and guide RNA, which steers Cas9 to the specific genetic sequence requiring modification. After the targeted DNA strand is cut, the cell’s inherent repair processes activate, allowing researchers to implement changes to the genetic material.
In contrast to previous tools that relied on challenging-to-reprogram proteins, CRISPR’s RNA-guided approach offers greater flexibility, easier design, and high precision. This ease and accuracy have enabled CRISPR’s application in fields like medicine, agriculture, manufacturing, and microbiology—such as designing microbes to enhance product yields. Nonetheless, as this article discusses, with expanding capabilities come increasing ethical dilemmas, particularly concerning germline editing and genetic enhancement.
First Patient to Receive a Tailored CRISPR Treatment
In February 2025, the first tailored CRISPR treatment was administered to an infant named KJ to address a deficiency in Carbamoyl Phosphate Synthetase 1 (CPS1)—an enzyme crucial for converting ammonia (produced during protein metabolism) into urea. A team headed by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia developed this treatment following extensive research in gene editing and collaboration with other medical professionals.
Their efforts concentrated on disorders impacting the urea cycle, leading to harmful levels of ammonia that damage organs such as the brain and liver. The treatment was customized specifically for KJ’s unique CPS1 deficiency utilizing preclinical findings on analogous variants.
To date, the only CRISPR therapies authorized by the U.S. FDA have been for more prevalent conditions like sickle cell disease and beta thalassemia, which impact tens or even hundreds of thousands of individuals. In KJ’s situation, his therapy was devised within six months of his birth, targeting his distinctive CPS1 variant. The team formulated a base editing therapy administered through lipid nanoparticles to his liver to rectify the defective enzyme.
The February treatment marked the initiation of a trilogy of doses; KJ received the subsequent two doses in March and April 2025. As of his final dose, he has not encountered any significant side effects, demonstrates enhanced tolerance to dietary protein, and requires reduced medication to regulate ammonia levels. While ongoing monitoring will be necessary, Ahrens-Nicklas notes that the results thus far are encouraging.
Ethical Issues Surrounding CRISPR
Like any pioneering technology, CRISPR raises intricate ethical dilemmas. Although its main intent is to edit somatic cells to treat ailments, it also has applications for gametes, entering the contentious area of germline editing. Modifying DNA that will be passed down to future generations is frequently viewed as unethical—particularly when aimed at enhancing traits instead of addressing medical conditions.
In response to these apprehensions, researchers have temporarily suspended germline editing until its ethical and societal repercussions are more thoroughly comprehended. The unpredictability associated with genetic modifications and the enduring nature of these changes throughout generations prompts essential inquiries regarding where to establish limits on such practices.